Role of thromboxane receptor antagonists in cardiovascular disease.
A number of reports indicate the TX receptor antagonists may be useful in preventing coronary artery reocclusion following fibrinolytic therapy, reducing myocardial ischemia/reperfusion injury and consequent neutrophil accumulation, preventing thrombocardiac sudden death, and attenuating the sequelae of endotoxic shock. Limited clinical studies have been initiated, and no adverse clinical effects can be associated with specific TX receptor blockade. Further clinical studies will be required to confirm the provocative animal studies, as well as defining the role of TX as a mediator of coronary vasospasm, respiratory disorders, and renal failure and rejection episodes.
Smith
E F
EF
Department of Pharmacology, Smith Kline and French Laboratories, King of Prussia, PA 19406.
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D003328:Coronary Thrombosis / Q000188:drug therapy; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011982:Receptors, Prostaglandin / Q000502:physiology; D017482:Receptors, Thromboxane; D012772:Shock, Septic / Q000188:drug therapy; D013928:Thromboxane A2 / Q000494:pharmacology / Q000502:physiology
D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013928:Thromboxane A2